{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/immunizations-pneumococcal/management/children-diagnosed-at-increased-risk-under-2-years-of-age/","result":{"pageContext":{"chapter":{"id":"8f83b7e0-d764-5bca-a03b-e549e24f402a","slug":"children-diagnosed-at-increased-risk-under-2-years-of-age","fullItemName":"Scenario: Children diagnosed at increased risk under 2 years of age","depth":2,"htmlHeader":"<!-- begin field 5a35086a-baa5-40c7-bba8-e104b3dca903 --><h2>Scenario: Children at diagnosed at increased risk under 2 years of age</h2><!-- end field 5a35086a-baa5-40c7-bba8-e104b3dca903 -->","summary":"Covers the management of children younger than 2 years of age who are diagnosed at high risk of pneumococcal disease.","htmlStringContent":"<!-- begin item 1cd02904-2f9a-4e2e-9b76-866824d83377 --><!-- begin field 25bb56d6-334c-4b40-912f-acd900ae19e3 --><p>From age 2 months to 23 months.</p><!-- end field 25bb56d6-334c-4b40-912f-acd900ae19e3 --><!-- end item 1cd02904-2f9a-4e2e-9b76-866824d83377 -->","topic":{"id":"af89c4a4-b7c5-5032-9cab-157c542f213b","topicId":"667146c4-e374-494f-a050-b8976e5e7056","topicName":"Immunizations - pneumococcal","slug":"immunizations-pneumococcal","lastRevised":"Last revised in January 2021","chapters":[{"id":"c2a8d969-5d35-5185-b666-883786b066c5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9db009c1-59ed-5d79-9446-33e54e1676c7","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"cf4adec7-88ef-5a0f-b072-53bd3049b260","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"5459dd7c-ac40-5828-8bec-840fa7fca764","slug":"changes","fullItemName":"Changes"},{"id":"197178ce-11cd-52df-883c-419e06744dd4","slug":"update","fullItemName":"Update"}]},{"id":"95a44f6b-2987-5086-8656-ef21fcbbc28b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"006db835-5d01-5085-a6e1-ee57f7ca41c8","slug":"goals","fullItemName":"Goals"},{"id":"29af8dc8-13e9-56c4-a041-b00bbf320b1e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e7b32647-3434-5f3f-b8be-51203e3ebfee","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ebc71bdc-4766-5946-bb16-121b9da544f3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3daf6a12-bce0-53d4-a318-05cc49aab107","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4dce4bc5-1119-5c5d-9422-d275fc956a4e","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"002fbb60-3041-597d-9d3d-fc3a17068591","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"37c59838-49d0-51d5-8203-1eae848738c2","slug":"definition-of-pneumococcal-disease","fullItemName":"Definition of pneumococcal disease"},{"id":"aba9a3c5-f0f7-5e65-b369-1947461d0158","slug":"prevalence-of-pneumococcal-disease","fullItemName":"Prevalence of pneumococcal disease"},{"id":"9da9e662-ccc4-5bc4-bae8-eb3f0ec80b19","slug":"risk-factors-for-pneumococcal-disease","fullItemName":"Risk Factors for pneumococcal disease"},{"id":"492f20c5-5e03-51dc-9ccb-1994f3db1c35","slug":"pneumococcal-immunization","fullItemName":"Pneumococcal immunization"}]},{"id":"e183f01f-d538-542b-bc16-6f849966d1d2","fullItemName":"Management","slug":"management","subChapters":[{"id":"b036915e-0e64-5fea-a247-9777822304b3","slug":"routine-vaccination-of-infants-adults-over-65-years-of-age","fullItemName":"Scenario: Routine vaccination of infants, and adults over 65 years of age"},{"id":"8f83b7e0-d764-5bca-a03b-e549e24f402a","slug":"children-diagnosed-at-increased-risk-under-2-years-of-age","fullItemName":"Scenario: Children diagnosed at increased risk under 2 years of age"},{"id":"c9787edf-835f-54d9-9b86-b7c8695307ef","slug":"children-diagnosed-at-increased-risk-aged-2-5-years","fullItemName":"Scenario: Children diagnosed at increased risk aged 2-5 years"},{"id":"7f443a07-5081-5296-b56e-8b82550f8c52","slug":"children-over-5-years-of-age-adults-diagnosed-at-increased-risk","fullItemName":"Scenario: Children over 5 years of age and adults diagnosed at increased risk"}]},{"id":"f17e101b-7bea-59aa-9b9c-46924bbfdc2b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"871f5861-588e-57ef-9521-0a81e77d4583","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d0a50959-6448-5a18-8845-f75f5c40f388","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"92b33782-e97b-565d-b432-b19376ecedbc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5b1e27f9-71f0-5238-978b-5648b601e292","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2b6c5d09-7606-5742-89c4-19fa3b671fd7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"037af05f-e510-5862-b316-4676f7c3a61e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"04bd9328-ed11-5b9d-ba9a-06584ecd6f33","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e183f01f-d538-542b-bc16-6f849966d1d2","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"9f499ca0-9b0e-5c06-81a5-83e14ec3b8ac","slug":"children-under-2-years-of-age","fullItemName":"Children under 2 years of age","depth":3,"htmlHeader":"<!-- begin field a3ac85cb-0c2c-45fc-9082-9a4e791763c7 --><h3>How should I vaccinate children diagnosed at increased risk under 2 years of age?</h3><!-- end field a3ac85cb-0c2c-45fc-9082-9a4e791763c7 -->","summary":null,"htmlStringContent":"<!-- begin item 0caf6a2e-1e84-4af1-b030-2effb227aad1 --><!-- begin field e8d8be6b-2b04-4b7c-aa09-6a84336ce4b6 --><ul><li><strong>People at increased risk of pneumococcal disease or complications include those with:</strong><ul><li>Asplenia or splenic dysfunction.</li><li>Chronic respiratory, heart, liver, or kidney disease.</li><li>Diabetes requiring insulin or oral hypoglycaemic drugs.</li><li>Immunosuppression due to a medical condition or treatment.</li><li>Cochlear implants.</li><li>Cerebrospinal fluid leaks (including leakage following trauma or major skull surgery).<ul><li>For more details, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/background-information/risk-factors-for-pneumococcal-disease/\">Risk factors</a>.</li></ul></li></ul></li><li><strong>Offer all infants younger than 1 year of age who are diagnosed at increased risk of pneumococcal disease</strong> the 13-valent pneumococcal conjugate vaccine (PCV13) (Prevenar 13<sup>®</sup>), according to the <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/management/routine-vaccination-of-infants-adults-over-65-years-of-age/#routine-infant-pneumococcal-vaccination\">routine immunization schedule</a>, at 2, 4, and 12 months of age.<ul><li>Premature infants should be immunized at the appropriate chronological age.</li></ul></li><li><strong>Infants who present late for vaccination should receive two doses of PCV13 before the age of 1 year (if possible), with a further dose at 12 months of age.</strong> Ideally, doses should be two months apart but can be given one month apart if necessary to ensure the immunization schedule is completed by 1 year of age. </li><li><strong>Offer unimmunized at-risk children aged over 1 but less than 2 years without asplenia, splenic dysfunction, or significant immunosuppression the routine 12-month PCV13 booster only. This can be given any time up to the second birthday. </strong><ul><li><strong>At-risk children in this age group who have asplenia or splenic dysfunction, or who are immunocompromised (including bone marrow transplant recipients, children with acute and chronic leukaemia, or genetic disorders affecting the immune system) should be given a second dose of PCV13 two months after the first dose.</strong></li></ul><strong> </strong></li><li><strong><strong>Offer all at-risk children a dose of pneumococcal polysaccharide vaccine (PPV23)(Pneumovax<sup>®</sup>) after their second birthday</strong> and at least 2 months after the last PCV13 dose.</strong></li><li><strong>If there is no reliable immunization history, it should be assumed that the infant/child has not been vaccinated.</strong></li></ul><!-- end field e8d8be6b-2b04-4b7c-aa09-6a84336ce4b6 --><!-- end item 0caf6a2e-1e84-4af1-b030-2effb227aad1 -->","subChapters":[{"id":"a1e5c87e-0cba-51eb-b41f-c65716906646","slug":"basis-for-recommendation-16f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b44cd7c9-79ee-4ca3-a792-cb8a2ac43739 --><h4>Basis for recommendation</h4><!-- end field b44cd7c9-79ee-4ca3-a792-cb8a2ac43739 -->","summary":null,"htmlStringContent":"<!-- begin item 16fe2772-b6f6-490c-a76c-9379a16df6aa --><!-- begin field 37ea4679-bbef-43f4-b95c-9c4fe444e296 --><p>The recommendations on pneumococcal immunization are based on government policy as discussed in Chapter 25 of <em>Immunisation against infectious disease</em> (the 'Green Book'), published by the Department of Health [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013a</a>].</p><h5>Unimmunized or partially immunized children</h5><ul><li>The recommendations on immunization schedule for unimmunized or partially immunized children are based on the Public Health England (PHE) document <em>Vaccination of individuals with uncertain or incomplete immunisation status </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2015</a>].</li></ul><h5>Additional PCV13 booster for unimmunized at-risk children aged 1–2 years with asplenia/splenic dysfunction/immunosuppression</h5><ul><li>An additional PCV13 booster is recommended for this group as they may have a sub-optimal immunological response to the first dose of vaccine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013a</a>].</li></ul><!-- end field 37ea4679-bbef-43f4-b95c-9c4fe444e296 --><!-- end item 16fe2772-b6f6-490c-a76c-9379a16df6aa -->","subChapters":[]}]},{"id":"d7524534-01e2-55af-b3de-14d392d69d02","slug":"advice-for-parents","fullItemName":"Advice for parents","depth":3,"htmlHeader":"<!-- begin field ac171d21-5d4a-4fde-8870-eb276848f3b8 --><h3>What advice to give to parents</h3><!-- end field ac171d21-5d4a-4fde-8870-eb276848f3b8 -->","summary":null,"htmlStringContent":"<!-- begin item c3f4019a-e0fe-4497-9016-3cc9fa9748f7 --><!-- begin field 4daaee03-375c-421f-9aba-dfe5c659d28a --><ul><li><strong>Explain the benefits of vaccination,</strong> in particular that it helps prevent a major cause of meningitis in young children. <ul><li>Information about <a href=\"https://www.nhs.uk/conditions/vaccinations/\" data-hyperlink-id=\"df801355-872a-44f7-b350-aa5600d5a774\">vaccinations</a> (including the UK childhood immunization schedule, vaccine safety, risks and benefits, and individual vaccines) is available on the <a href=\"https://www.nhs.uk/conditions/\" data-hyperlink-id=\"5e845d9d-7d89-4e19-b105-aa5600d5a786\">NHS</a> website.</li></ul></li><li><strong>Reassure that vaccinations are safe, and serious adverse effects are very rare.</strong> Pain, swelling, and reddening at the site of injection are most common and systemic adverse effects, should they occur, are usually limited to mild fever.</li><li><strong>Advise parents or carers not to routinely give paracetamol or ibuprofen to prevent fever around the time of vaccination.</strong> However if pain or fever is problematic after the child has been vaccinated, then paracetamol or ibuprofen may be used. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a>.</li><li><strong>Offer parents or carers written information,</strong> such as the Public Health England patient information leaflet <a data-hyperlink-id=\"15aca3b7-b1f2-4b03-b815-a9930057127d\" href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/448789/8584-what-to-expect-after-vaccination-2015-2P-A5-02-web.pdf\">What to expect after vaccinations</a>.</li></ul><!-- end field 4daaee03-375c-421f-9aba-dfe5c659d28a --><!-- end item c3f4019a-e0fe-4497-9016-3cc9fa9748f7 -->","subChapters":[{"id":"acb9219c-1961-5f50-9b03-46724a2a4495","slug":"basis-for-recommendation-8de","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 775646cd-c2f2-4428-8ca1-38878c3ba023 --><h4>Basis for recommendation</h4><!-- end field 775646cd-c2f2-4428-8ca1-38878c3ba023 -->","summary":null,"htmlStringContent":"<!-- begin item 8de17f17-88a1-45a9-a69d-2f3e06810340 --><!-- begin field 119f61f4-c436-47b5-a88d-f3802fdf61dc --><p>The recommendations on advice to give about pneumococcal immunization are based on information in the chapter on vaccine safety and adverse effects following immunization in <em>Immunisation against infectious disease</em> (the 'Green Book') published by Public Health England (PHE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013b</a>], and are pragmatic, based on what CKS considers to be good clinical practice.</p><h5>Explaining the benefits of vaccination</h5><ul><li>Many parents find the process of having their children immunized distressing. Explaining the benefits of vaccination and giving reassurance about the limited nature of any adverse effects should be helpful.</li></ul><h5>Using paracetamol or ibuprofen</h5><ul><li>CKS found no controlled trials on the efficacy of paracetamol or ibuprofen in reducing pain or fever following vaccination. As paracetamol and ibuprofen have been shown to reduce fever and pain in conditions such as the common cold and influenza [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">Eccles and Mason, 2001</a>] , it can be reasonably extrapolated that they may be effective in relieving these symptoms on an 'as required' basis after vaccination. PHE recommends that paracetamol or ibuprofen should not be given to prevent fever in children who receive pneumococcal vaccinations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013b</a>]. It states that there is no evidence that paracetamol or ibuprofen prevent febrile convulsions and that there is some evidence that they may lower antibody responses to some vaccines when given around the time of vaccination [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">Prymula et al, 2009</a>].</li></ul><!-- end field 119f61f4-c436-47b5-a88d-f3802fdf61dc --><!-- end item 8de17f17-88a1-45a9-a69d-2f3e06810340 -->","subChapters":[]}]},{"id":"187d8a8d-1f76-5590-b224-9953707362b3","slug":"how-to-administer-the-vaccine","fullItemName":"How to administer the vaccine","depth":3,"htmlHeader":"<!-- begin field fa5e75a6-867d-48d4-8693-437e2344d57a --><h3>How to administer the vaccine</h3><!-- end field fa5e75a6-867d-48d4-8693-437e2344d57a -->","summary":null,"htmlStringContent":"<!-- begin item 6bc3d8c3-22ef-4c2e-a4ba-c9d0b6a66a67 --><!-- begin field 39c2861b-98f5-403b-bbb5-6fafe5be5f19 --><ul><li><strong>Obtain written or verbal consent at the time of vaccination from a person with parental responsibility.</strong></li><li><strong>Ensure that:</strong> <ul><li>There are no contraindications to the vaccine.<ul><li>The only absolute contraindication to pneumococcal vaccination is a confirmed previous anaphylactic reaction to the vaccine or one of its components.</li></ul></li><li>The parent or carer has been fully informed about the vaccine and the vaccination procedure.</li><li>Possible adverse reactions have been discussed and the parent or carer is aware of how to manage them. </li><li>The vaccine is correct, has been stored appropriately, and has not expired. </li><li>The vaccination site has been washed with soap and water if it is visibly dirty. </li></ul></li><li><strong>For infants and children who are acutely unwell (for example with a fever or acute infection), postpone pneumococcal immunization until they have fully recovered.</strong> Minor illness without fever or systemic upset is not a valid reason to postpone immunization.</li><li><strong>Pneumococcal vaccines are usually given by intramuscular (IM) injection, </strong>into the upper arm in children, or the anterolateral thigh in infants under 1 year of age. However, if the infant/child has a bleeding disorder, the vaccine should be given by deep subcutaneous (SC) injection to reduce the risk of bleeding. <ul><li>Use a 25mm 23-gauge (blue) or 25-gauge (orange) needle for IM administration in most infants and children.<ul><li>In pre-term or very small infants, use a 16mm needle for IM injection. </li></ul></li></ul></li><li><strong>Pneumococcal vaccines can be given at the same time as other vaccines.</strong> If an additional vaccine is required on the same day, use separate limbs if possible, or inject at sites at least 2.5 cm apart. </li><li><strong>Record the date of administration, vaccine and product name, batch number, expiry date, dose administered, and site of administration for each vaccine.</strong> </li><li><strong>Observe the child after vaccination to detect immediate adverse reactions.</strong> Ensure any bleeding has stopped and check for any symptoms of anaphylaxis before they leave.<ul><li>Anaphylaxis is extremely rare, and usually becomes apparent within minutes. By the time the site has been checked for bleeding and documentation has been completed, most reactions will have become apparent. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li></ul></li></ul><!-- end field 39c2861b-98f5-403b-bbb5-6fafe5be5f19 --><!-- end item 6bc3d8c3-22ef-4c2e-a4ba-c9d0b6a66a67 -->","subChapters":[{"id":"9d435fca-c256-565d-b68e-fea5f725e5c4","slug":"basis-for-recommendation-1ed","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 942b7d91-cd4a-4155-b79f-bcd96023f1bc --><h4>Basis for recommendation</h4><!-- end field 942b7d91-cd4a-4155-b79f-bcd96023f1bc -->","summary":null,"htmlStringContent":"<!-- begin item 1ed884d9-fe04-4e6b-8e92-6d5ca0974b6d --><!-- begin field e165a4ad-f84e-4071-9a4d-0c68c72b1cdf --><p>These recommendations are based on chapters in<em> Immunisation against infectious disease</em> (the 'Green Book') published by Public Health England (PHE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013c</a>], [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013d</a>], [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013b</a>], and what CKS considers to be good clinical practice.</p><h5>Obtaining consent</h5><ul><li>Consent for immunizations does not legally have to be in writing, but must be given voluntarily by a fully informed person who is able to make and communicate their decision. For children not competent to give or withhold consent, a person with parental responsibility can provide this [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013d</a>].</li></ul><h5>Site of administration</h5><ul><li>The site of administration depends on the child's age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013d</a>]:<ul><li>The anterolateral aspect of the thigh is appropriate in children aged less than 1 year as the deltoid muscle is not considered to be well-enough developed for intramuscular injection.</li><li>Over the age of 1 year, vaccines are routinely given into the deltoid muscle as it is convenient, providing easy access, and it reduces the risk of localized reactions, which are common when vaccines are given subcutaneously.</li><li>The gluteal muscle should be avoided. The needle may not penetrate through adipose tissue into the muscle, and this may cause a poor immunological response to the vaccine. In addition, there is a risk of damage to underlying structures such as the sciatic nerve.</li></ul></li></ul><!-- end field e165a4ad-f84e-4071-9a4d-0c68c72b1cdf --><!-- end item 1ed884d9-fe04-4e6b-8e92-6d5ca0974b6d -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}